Research Article
Does Cytomegalovirus Develop Resistance following Antiviral Prophylaxis and Treatment in Renal Transplant Patients in Kuwait?
Table 3
Characteristics and outcomes of six patients with clinically suspected drug-resistant CMV.
| Patient no. | Age/sex | Clinical symptoms | Drug/regimen | Duration of drug exposure | CMV DNA copy no. (log10/mL) | At the beginning of therapy | After therapy |
| 1 | 43/F | Fever, leukopenia, thrombocytopenia, pneumonia | VGCV/treatment | 3 weeks | 4.2 | 2.1 |
| 2 | 47/F | Fever, leukopenia, graft rejection | GCV/treatment and maintenance | 2 weeks treatment and 3 months maintenance | 4.1 | 2.3 |
| 3 | 60/M | Leukopenia | VGCV/prophylaxis, GCV & VGCV/treatment | 2 weeks prophylaxis, 2 weeks + 3 months treatment | 4.9 | 3.9 |
| 4 | 54/F | Fever, leukopenia | GCV/treatment | 2 weeks | 4.8 | 3.5 |
| 5 | 55/F | Fever, leukopenia, high creatinene, diarrhoea | GCV & VGCV/treatment | 3 weeks | 2.8 | 1.7 |
| 6 | 34/F | Fever, leukopenia, renal failure, bleeding | GCV/prophylaxis, GCV & VGCV/treatment | 2 week prophylaxis, 3 months treatment | 2.9 | 1.7 |
|
|